Evidence-based management of adult patients with diffuse glioma Authors' reply
We appreciate the interest of our colleagues representing the European Low-Grade Glioma Network in the updated European Association for Neuro-Oncology (EANO) guidelines. 1 Such guidelines often represent a multidisciplinary consensus that aims at providing guidance also in areas where evidence from conclusive clinical studies is limited or absent. Our colleagues miss a specific reference to the value of radiological growth rates.
If we did not think that the assessment of tumour growth by neuroimaging was important, we would not have recommended regular MRI scanning to determine benefit from treatment and the need for re-intervention. However, no prospective systematic outcome study informs us on how to integrate radiological growth rates into clinical decision making, notably about timepoints of interventions. Furthermore, our colleagues are at odds with our assessment of the scientific literature on the role of surgery for adult patients with glioma. Yet, our assessment of the evidence, which is a result of multidisciplinary consensus involving leading neurosurgeons in Europe, is fully consistent with the current Cochrane review, 2 which reinforces the need for randomised controlled clinical trials in this situation. We agree that the recent long-term followup on the Norwegian cohort study is suggestive of a benefit of early surgical intervention in patients with low grade gliomas across the major molecular subtypes 3 and might in fact be the best evidence for a role of early surgery in this population published so far. 4 Yet, this cohort study cannot be considered as conclusive evidence about the value of resection. Moreover, the article was not available in the public domain when we prepared the EANO guideline. 
